A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

Genentech, Inc.

Overview

This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients. Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study.

Study Type

OBSERVATIONAL

Conditions

Carcinoma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Signed Informed Consent Form * Enrollment in one of a list of certain randomized, controlled bevacizumab trials Exclusion Criteria: * Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD) * Congenital long QT syndrome * Family history of long QT syndrome * Clinically significant bradycardia (defined as \< 50 beats/minute)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.